Allogeneic Hematopoietic Stem Cell Transplantation, CMV Infection
Conditions
Brief summary
This is a single centre, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating refractory CMV infection after HSCT.
Detailed description
CMV infection is a major and potentially life-threatening complication after allogenic hematopoietic stem cell transplantation (allo-SCT). Pharmacotherapy with ganciclovir and foscarnet remains the mainstay of treatment and has significantly improve clinical results, however, it is unsatisfactory owing to toxicity, limited efficacy and risk of developing resistance. In recent years, adoptive T cell therapy has been proposed as an alternative option for CMV infection after allo-SCT. However, patients with transplants from CMV-negative donors are at highest risk, and an adoptive therapy is missing because CMV-specific T cells are not available. CMV TCR-transduced donor-derived T Cells (CMV-TCR-T cells) is an attractive strategy to specifically redirect T-cell immunity toward CMV. In this prospective clinical phase I trial, we propose to evaluate the safety and efficacy of stem cell donor-derived CMV-TCR-T cells for patients with refractory CMV infection after allo-SCT. Donor derived CMV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.3-1×10E7CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
Interventions
BIOLOGICALCMV-TCR-T cells
Patients who developed refractory CMV infection after allo-HSCT will be enrolled, and donor derived CMV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.3-1×10E7CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
Sponsors
Xiao-Jun Huang
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with acute leukemia (AL) or myelodysplastic syndrome (MDS) who receive haploid allogeneic hematopoietic stem cell transplantation, pre-transplantation assessment ≤CR2; 2. Age 18-60, including boundary value, gender unlimited; 3. Refractory CMV infection occurred in the early stage of transplantation : After 2 weeks of standard antiviral treatment, the CMV DNA copy number continued to be ≥1000 copies/mL, and the CMV DNA copy number at the beginning of the treatment decreased by \<log10 ； 4. The transplant donor's HLA-A matching is one of 2402, 0201 or 1101, and the physical examination is qualified; 5. ECOG ≤ 3, estimated life expectancy\> 3 months; 6. Patients who voluntarily sign informed consent and are willing to comply with treatment plans, visit arrangements, laboratory tests and other research procedures.
Exclusion criteria
1. Patients with active aGVHD III-IV and / or mild and severe cGVHD; 2. Have received cell therapy such as DLI, CTL, CAR-T, NK or participated in any other clinical research on drugs and medical devices; 3. Patients who have developed CMV disease; 4. patients with organ failure: * Heart: NYHA heart function grade IV; * Liver: Grade C that achieves Child-Turcotte liver function grading; * Kidney: kidney failure and uremia; * Lung: symptoms of respiratory failure; * Brain: a person with a disability; 5. Pregnant or lactating women; 6. The researchers found that it was unsuitable for the recipients to be enrolled.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | 3 months | Percentage of participants with adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes of CMV-DNA copies | 3 months | Changes of CMV-DNA copies |
| CMV-specific immunity reconstitution | 3 months | In vivo persistence of the infused CMV-TCR-T cells and reconstitution of CMV-specific immunity |
Countries
China
Contacts
Primary ContactLanping Xu, PhD,MD
Backup ContactXuying Pei, PhD
Outcome results
None listed